Efficacy News and Research

RSS

ASN Annual Meeting to highlight six late-breaking clinical trials on nephrology

Six late-breaking clinical trials have been accepted for presentation next week during the American Society of Nephrology's 43rd Annual Meeting and Scientific Exposition in Denver, CO. These trials were selected based upon their potential impact to the field of nephrology.

12 Nov 2010

Oligomerix receives SBIR Phase II grant to develop drugs for Alzheimer’s disease

Oligomerix, Inc. today announced the receipt of a two-year Small Business Innovation Research (SBIR) Phase II grant for $1.6M from the National Institute on Aging, National Institutes of Health (NIH), for a program to discover small molecules and antibodies targeting tau protein oligomers in the development of disease modifying therapeutics for Alzheimer's disease.

12 Nov 2010

NephRx initiates NX001 Phase I clinical trial to prevent DGF in kidney transplant patients

NephRx Corporation today announced that it has initiated a Phase I clinical trial of its lead compound NX001 and has successfully dosed the first subject in the study. NX001, a kidney growth factor peptide that has demonstrated good safety and promising efficacy in two animal models of acute renal failure, is in development for the prevention of delayed graft function (DGF) in kidney transplantation patients.

11 Nov 2010

Think treatments for cancer, diabetes don't grow on trees? Think again

Supported by thousands of years of use, a new wave of polymolecular botanical drugs (PBDs), backed by strong biomedical research and clinical trials, are growing in acceptance as a viable new drug category for the treatment and prevention of a wide spectrum of diseases from cancer to obesity.

11 Nov 2010

BIOTRONIK releases Pulsar-18 stent for treatment of long lesions in superficial femoral, infrapopliteal arteries

BIOTRONIK AG, a European manufacturer of therapy solutions for vascular intervention, has announced the international full market release of the innovative Pulsar-18 stent for treatment of long lesions in the superficial femoral and infrapopliteal arteries. Pulsar-18 is unique in the market, representing an advance in technology that further reinforces the company's position as a leader in providing high quality technologies for patients with peripheral vascular disease.

11 Nov 2010

Bed rest may not delay preterm births, says Frances Payne professor

Despite lack of evidence about bed rest's effectiveness, doctors annually prescribe it for roughly 1 million pregnant women to delay preterm births.

11 Nov 2010

Discovery of anti-parasitic drug mechanism could lead to new treatments for filarial diseases

In a major breakthrough that comes after decades of research and nearly half a billion treatments in humans, scientists have finally unlocked how a key anti-parasitic drug kills the worms brought on by the filarial diseases river blindness and elephantitis.

11 Nov 2010

News stories about cancer contain language that contribute to public uncertainty

New research from North Carolina State University shows that most online news stories about cancer contain language that likely contributes to public uncertainty about the disease a significant finding, given that at least one-third of Americans seek health information online.

11 Nov 2010

Evotec revenues increase 33% to € 38.8 m during first nine months of 2010

Evotec AG today reported financial results and a corporate update for the first nine months of 2010.

11 Nov 2010

Incyte presents data on INCB28050 Phase IIa trial for rheumatoid arthritis at ACR/ARHP Meeting

Incyte Corporation announced the presentation of final six-month clinical data from the dose ranging, placebo-controlled Phase IIa trial of its orally available janus kinase (JAK) inhibitor INCB28050 in patients with active rheumatoid arthritis (RA).

11 Nov 2010

4SC 2010 first nine months revenue decreases from EUR1.4 million to EUR0.8 million

4SC, a drug discovery and development company focused on autoimmune and cancer indications, today announced its financial results in accordance with International Financial Reporting Standards (IFRS) for the first nine months of 2010, which ended on 30 September 2010.

11 Nov 2010

Cortex applauds Servier for intent to move High Impact AMPAKINE compound into Phase I clinical studies

Cortex Pharmaceuticals, Inc. announced that it had been notified by Les Laboratoires Servier ("Servier"), France's largest privately held pharmaceutical company, of their intent to move forward into Phase I clinical studies with the jointly-discovered High Impact AMPAKINE® compound S47445 (CX1632).

11 Nov 2010

Hygeia completes HYG-102 preclinical studies for vulvar and vaginal atrophy, and age-related skin fragility

Hygeia Therapeutics, Inc. announced today the successful completion of a series of preclinical studies for HYG-102, their lead product for the treatment of vulvar and vaginal atrophy (VVA) and age-related skin fragility. HYG-102 is the lead biodegradable estrogenic candidate in a portfolio of 23 similar compounds licensed from the laboratory of Dr. Richard Hochberg of Yale University.

11 Nov 2010

Watson’s Uracyst pilot study for interstitial cystitis fails to demonstrate efficacy endpoints

Watson Pharmaceuticals, Inc. today announced that the U.S. pilot study evaluating Uracyst (sodium chondroitin sulfate solution 2.0%) for the treatment of interstitial cystitis did not meet predefined efficacy endpoints.

11 Nov 2010

PolyMedix receives FDA regulatory clearance for PMX-30063 IND application

PolyMedix, Inc. an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, has received regulatory clearance from the United States Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for PMX-30063, a synthetic defensin-mimetic antibiotic.

11 Nov 2010

Nutech Mediworld founder presents clinical study results of hESC therapy in patients with spinal cord injury

Dr. Geeta Shroff, founder & medical director of Nutech Mediworld, presented today the summary results of a retrospective clinical study of human embryonic stem cell (hESC) therapy in patients with chronic spinal cord injury (SCI).

11 Nov 2010

Amarin reports $31.4 million cash balance for third quarter 2010

Amarin Corporation plc, a clinical-stage biopharmaceutical company focused on cardiovascular disease, today reported its financial and operational results for the three-month period ended September 30, 2010.

10 Nov 2010

Receptive music therapy associated with reduced depressive symptoms

A Swedish study that appears in the current issue of Psychotherapy and Psychosomatics applies music therapy to the treatment of depression.

10 Nov 2010

Hospitals need to work more to prevent heart attack deaths: Study

Door-to-balloon time has dropped dramatically as hospitals rush heart attack patients into treatment, but a five-year study released Monday shows quicker hospital care has not saved more lives.

10 Nov 2010

Covidien analysis finds lower incidence of GI adverse events with topical NSAIDs versus oral

Covidien, a leading global provider of healthcare products, announced the results of an analysis that will be presented at the American College of Rheumatology's Annual Scientific Meeting. A pooled analysis of safety data suggests that patients with knee osteoarthritis (OA) receiving the topical PENNSAID® (diclofenac sodium topical solution) 1.5% w/w had significantly fewer gastrointestinal (GI)-related adverse events than those receiving an oral non-steroidal anti-inflammatory drug (NSAID).

10 Nov 2010

Efficacy News and Research

ASN Annual Meeting to highlight six late-breaking clinical trials on nephrology

Oligomerix receives SBIR Phase II grant to develop drugs for Alzheimer’s disease

NephRx initiates NX001 Phase I clinical trial to prevent DGF in kidney transplant patients

Think treatments for cancer, diabetes don't grow on trees? Think again

BIOTRONIK releases Pulsar-18 stent for treatment of long lesions in superficial femoral, infrapopliteal arteries

Bed rest may not delay preterm births, says Frances Payne professor

Discovery of anti-parasitic drug mechanism could lead to new treatments for filarial diseases

News stories about cancer contain language that contribute to public uncertainty

Evotec revenues increase 33% to € 38.8 m during first nine months of 2010

Incyte presents data on INCB28050 Phase IIa trial for rheumatoid arthritis at ACR/ARHP Meeting

4SC 2010 first nine months revenue decreases from EUR1.4 million to EUR0.8 million

Cortex applauds Servier for intent to move High Impact AMPAKINE compound into Phase I clinical studies

Hygeia completes HYG-102 preclinical studies for vulvar and vaginal atrophy, and age-related skin fragility

Watson’s Uracyst pilot study for interstitial cystitis fails to demonstrate efficacy endpoints

PolyMedix receives FDA regulatory clearance for PMX-30063 IND application

Nutech Mediworld founder presents clinical study results of hESC therapy in patients with spinal cord injury

Amarin reports $31.4 million cash balance for third quarter 2010

Receptive music therapy associated with reduced depressive symptoms

Hospitals need to work more to prevent heart attack deaths: Study

Covidien analysis finds lower incidence of GI adverse events with topical NSAIDs versus oral

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News